Sectors
IVA
Inventiva S.A.
3.78
1 x 4.55
4 x 4.45
bid
ask
+
0.03
0.80%
3 @ 06:58 PM
3.78 +0.00 (0.00%)
| Ytd | -18.71% | |
| 1y | -30.26% |
3.66
day range
3.82
3.41
52 week range
7.15
| Open | 3.79 | Prev Close | 3.75 | Low | 3.66 | High | 3.82 | Mkt Cap | 892.91M |
| Vol | 1.05M | Avg Vol | 1.14M | EPS | -2.19 | P/E | N/A | Forward P/E | -5.34 |
| Beta | 0.92 | Short Ratio | 3.38 | Inst. Own | 41.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-28 | 50-d Avg | 4.53 | 200-d Avg | 5.07 | 1yr Est | 14.62 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-09-25 | 2026-06 | -0.2 | N/A | N/A | N/A |
| 2026-03-30 | 2025-12 | -0.23 | -1.07 | -0.84 | -365.22% |
| 2025-09-25 | 2025-06 | -0.41 | -1.89 | -1.48 | -361.73% |
| 2025-03-26 | 2024-12 | -0.44 | -2.19 | -1.75 | -398.10% |
| 2024-09-25 | 2024-06 | -0.56 | -1.01 | -0.45 | -81.10% |
| 2024-03-27 | 2023-12 | -0.4 | -1.25 | -0.85 | -211.66% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-17 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2026-03-19 | Truist Securities | Upgrade | Buy | |
| 2026-01-28 | Barclays | Upgrade | Overweight | |
| 2026-01-12 | Leerink Partners | Upgrade | Outperform | |
| 2025-11-18 | Guggenheim | Upgrade | Buy | Buy |
| 2025-11-06 | Wolfe Research | Upgrade | Outperform |
Profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Caligan Partners, LP | 8.16M | 36.33M | 3.91% |
| 2026-06-29 | Samsara BioCapital, LLC | 6.31M | 28.10M | 3.02% |
| 2026-06-29 | Paradigm Biocapital Advisors LP | 4.00M | 17.80M | 1.91% |
| 2026-06-29 | Andera Partners | 3.63M | 16.17M | 1.74% |
| 2026-06-29 | Adar1 Capital Management, LLC | 3.61M | 16.05M | 1.73% |
| 2026-06-29 | Millennium Management Llc | 3.51M | 15.63M | 1.68% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | abrdn World Healthcare Fund | 1.21M | 5.40M | 0.58% |
| 2026-06-29 | abrdn Life Sciences Investors | 1.09M | 4.87M | 0.52% |
| 2026-04-29 | Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 969.59K | 4.31M | 0.46% |
| 2026-07-30 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 685.40K | 3.05M | 0.33% |
| 2026-06-29 | iShares Trust-iShares MSCI EAFE Small-Cap ETF | 318.27K | 1.42M | 0.15% |
| 2026-06-29 | Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 313.48K | 1.39M | 0.15% |